The Biomarker Core provides state-of-the-art expertise and technology for the quantitation of metabolites of nicotine and tobacco smoke toxicants and carcinogens. This Core, housed in the new Cancer and Cardiovascular Research Building of the Masonic Cancer Center, University of Minnesota, is equipped with 14 mass spectrometers of various designs and has decades of experience in the application of mass spectrometry techniques for the measurement of metabolites of tobacco smoke compounds and other environmental agents. The following compounds (biomarkers of toxicant exposure and toxicants in the products) will be quantified in this core: 1. Total nicotine equivalents, the sum of total nicotine, total cotinine, total 3?-hydroxycotinine and nicotine N- oxide in urine (total refers to the free analyte and its glucuronide conjugate). These compounds account for >85% of the nicotine dose. 2. Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the sum of free NNAL and its O- and N- glucuronides. NNAL is a metabolite of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (NNK), found in the urine of all tobacco users, but never in non-users unless they have been exposed to secondhand tobacco smoke. 3. Mercapturic acids of the toxicants acrolein, crotonaldehyde, benzene, and acrylonitrile. 4. Anatabine, a minor tobacco alkaloid to be used to quantify the use of usual brand cigarettes when the study requires the use of very low nicotine content cigarettes (low in anatabine), but allows the use of e-cigarettes or nicotine replacement therapies (NRT). 5. The ratio of 3-hydroxycotinine to cotinine in saliva as a measure of nicotine metabolism, 6. Toxic and carcinogenic constituents in smokeless tobacco and in e cigarette liquid and vapor: nicotine, anatabine and other minor tobacco alkaloids, NNK, and volatile toxicants acrolein, crotonaldehyde, benzene, and acrylonitrile.

Public Health Relevance

Smoking-related lung cancer is the leading cause of cancer death in the United States and worldwide. This program project grant investigates the use of very low nicotine cigarettes to facilitate smoking cessation. This Core facility will measure nicotine metabolites and tobacco toxicants in urine to provide a quantitate measure of a smokers exposure to these toxicants when using tobacco products and e-cigarettes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
7U54DA031659-07
Application #
9442731
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-02-28
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Villanti, Andrea C; Gaalema, Diann E; Tidey, Jennifer W et al. (2018) Co-occurring vulnerabilities and menthol use in U.S. young adult cigarette smokers: Findings from Wave 1 of the PATH Study, 2013-2014. Prev Med 117:43-51
Pericot-Valverde, Irene; Elliott, Rebecca J; Miller, Mollie E et al. (2018) Posttraumatic stress disorder and tobacco use: A systematic review and meta-analysis. Addict Behav 84:238-247
Denlinger-Apte, Rachel L; Tidey, Jennifer W; Koopmeiners, Joseph S et al. (2018) Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. Tob Control :
Parker, Maria A; Streck, Joanna M; Bergeria, Cecilia L et al. (2018) Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. Tob Regul Sci 4:84-91
Kazi, Abid; Fazzi, Alyse; Krebs, Nicolle M et al. (2018) Cigarette Management System: An operating procedures guide to obtaining and managing investigational tobacco products for regulatory science research. Contemp Clin Trials Commun 11:69-74
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118
Hatsukami, Dorothy K; Donny, Eric C (2018) The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller. Nicotine Tob Res :
Smith, Tracy T; Hatsukami, Dorothy K; Benowitz, Neal L et al. (2018) Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. Prev Med 117:8-14
Dermody, Sarah S; McClernon, F Joseph; Benowitz, Neal et al. (2018) Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence. Exp Clin Psychopharmacol 26:223-232

Showing the most recent 10 out of 63 publications